The targetable G protein proteome: Where is the next generation of drug targets?

Drug Discovery Today: TARGETS

Volumn 3, Issue 3, 2004, Pages 104-111

  Rebois, R Victor ^a   Allen, Bruce G ^b   Hébert, Terence E ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

7TM receptors; Cell biology; Drug Discovery; G proteins; Genetics; peptidomimetic; Pharmacology; protein complexes; proteomics; signalling specificity

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; LIPOSOME; PROTEIN DERIVATIVE; PROTEOME; SMAD PROTEIN;

BIOLUMINESCENCE; COMPLEX FORMATION; DOWN REGULATION; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG TARGETING; FLUORESCENCE ANALYSIS; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TECHNIQUE; X RAY CRYSTALLOGRAPHY;

EID: 12344307930     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1741-8372(04)02429-6     Document Type: Review

References (93)

1. Hurowitz E.H., et al. Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res. 7:2000;111-120
2. Lee A., et al. Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family. Genomics. 81:2003;245-248
3. Fredriksson R., et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63:2003;1256-1272
4. Gudermann T., et al. Diversity and selectivity of receptor-G protein interaction. Annu. Rev. Pharmacol. Toxicol. 36:1996;429-459
5. Gudermann T., et al. Functional and structural complexity of signal transduction via G-protein-coupled receptors. Annu. Rev. Neurosci. 20:1997;399-427
6. Lachance M., et al. Stable association of G proteins with beta 2AR is independent of the state of receptor activation. Cell. Signal. 11:1999;523-533
7. Wang Q., et al. Ribozyme-mediated suppression of the G protein gamma7 subunit suggests a role in hormone regulation of adenylylcyclase activity. J. Biol. Chem. 272:1997;26040-26048
8. Wang Q., et al. Ribozyme approach identifies a functional association between the G protein beta1gamma7 subunits in the beta-adrenergic receptor signaling pathway. J. Biol. Chem. 274:1999;17365-17371
9. Wang Q., et al. Differential dependence of the D1 and D5 dopamine receptors on the G protein gamma 7 subunit for activation of adenylylcyclase. J. Biol. Chem. 276:2001;39386-39393
10. Schwindinger W.F., et al. Loss of G protein gamma 7 alters behavior and reduces striatal alpha(olf) level and cAMP production. J. Biol. Chem. 278:2003;6575-6579
11. Robillard L., et al. G-beta-gamma subunit combinations differentially modulate receptor and effector coupling in vivo. Cell. Signal. 12:2000;673-682
12. Kleuss C., et al. Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents. Nature. 353:1991;43-48
13. Kleuss C., et al. Different beta-subunits determine G-protein interaction with transmembrane receptors. Nature. 358:1992;424-426
14. Kleuss C., et al. Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science. 259:1993;832-834
15. Kalkbrenner F., et al. Subunit composition of G(o) proteins functionally coupling galanin receptors to voltage-gated calcium channels. EMBO J. 14:1995;4728-4737
16. Robishaw J.D., et al. Ribozymes as tools for suppression of G protein gamma subunits. Methods Mol. Biol. 237:2004;169-180
17. Albert P.R., Robillard L. G protein specificity: traffic direction required. Cell. Signal. 14:2002;407-418
18. Hébert T.E., Bouvier M. Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem. Cell Biol. 76:1998;1-11
19. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2:2001;274-286
20. Rios C.D., et al. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol. Ther. 92:2001;71-87
21. Davare M.A., et al. A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2. Science. 293:2001;98-101
22. Lavine N., et al. G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J. Biol. Chem. 277:2002;46010-46019
23. Mellado M., et al. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 20:2001;2497-2507
24. Hall R.A., et al. The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature. 392:1998;626-630
25. Hu L.A., et al. Beta 1-adrenergic receptor association with PSD-95. Inhibition of receptor internalization and facilitation of beta 1-adrenergic receptor interaction with N-methyl-D-aspartate receptors. J. Biol. Chem. 275:2000;38659-38666
26. Xu J., et al. Beta 1-adrenergic receptor association with the synaptic scaffolding protein membrane-associated guanylate kinase inverted-2 (MAGI-2). Differential regulation of receptor internalization by MAGI-2 and PSD- 95. J. Biol. Chem. 276:2001;41310-41317
27. Pak Y., et al. Direct binding of the beta 1 adrenergic receptor to the cyclic AMP-dependent guanine nucleotide exchange factor CNrasGEF leads to Ras activation. Mol. Cell. Biol. 22:2002;7942-7952
28. Levchenko A., et al. Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties. Proc. Natl. Acad. Sci. U. S. A. 97:2000;5818-5823
29. Port J.D., Bristow M.R. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J. Mol. Cell. Cardiol. 33:2001;887-905
30. Xiao R.P. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. Sci. STKE. 1:2001;RE15
31. Pierce K.L., Lefkowitz R.J. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2:2001;727-733
32. Ventura H.O., Kalapura T. Beta-blocker therapy and severe heart failure: myth or reality? Congest. Heart Fail. 9:2003;197-202
33. Goldstein S. Benefits of beta-blocker therapy for heart failure: weighing the evidence. Arch. Intern. Med. 162:2002;641-648
34. Xiao R.P., et al. Recent advances in cardiac beta(2)-adrenergic signal transduction. Circ. Res. 85:1999;1092-1100
35. Steinberg S.F. The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ. Res. 85:1999;1101-1111
36. Lavoie C., et al. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J. Biol. Chem. 277:2002;35402-35410
37. Lavoie C., Hébert T.E. Pharmacological characterization of putative beta1-beta2-adrenergic receptor heterodimers. Can. J. Physiol. Pharmacol. 81:2003;186-195
38. Leof E.B. Growth factor receptor signaling: location, location, location. Trends Cell Biol. 10:2000;343-348
39. Cong M., et al. Binding of the beta 2 adrenergic receptor to N-ethylmaleimide-sensitive factor regulates receptor recycling. J. Biol. Chem. 276:2001;45145-45152
40. Tsao P., et al. Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol. Sci. 22:2001;91-96
41. Tsao P.I., von Zastrow M. Diversity and specificity in the regulated endocytic membrane trafficking of G-protein-coupled receptors. Pharmacol. Ther. 89:2001;139-147
42. Boivin B., et al. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J. Biol. Chem. 278:2003;29153-29163
43. Gobeil F. Jr, et al. Nuclear prostaglandin signaling system: biogenesis and actions via heptahelical receptors. Can. J. Physiol. Pharmacol. 81:2003;196-204
44. Alto N., et al. Intracellular targeting of protein kinases and phosphatases. Diabetes. 51:(Suppl 3):2002;S385-S388
45. Dorn G.W. 2nd, Mochly-Rosen D. Intracellular transport mechanisms of signal transducers. Annu. Rev. Physiol. 64:2002;407-429
46. Carnegie G.K., Scott J.D. A-kinase anchoring proteins and neuronal signaling mechanisms. Genes Dev. 17:2003;1557-1568
47. Elion E.A. The Ste5p scaffold. J. Cell Sci. 114:2001;3967-3978
48. Smith F.D., Scott J.D. Signaling complexes: junctions on the intracellular information super highway. Curr. Biol. 12:2002;R32-R40
49. Pandey A., et al. Use of mass spectrometry to study signaling pathways. Sci. STKE. 1:2000;PL1
50. Mann M., et al. Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem. 70:2001;437-473
51. Yeung Y.G., Stanley E.R. Proteomic approaches to the analysis of early events in colony-stimulating factor-1 signal transduction. Mol. Cell. Proteomics. 2:2003;1143-1155
52. Bouwmeester T., et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat. Cell Biol. 6:2004;97-105
53. Knuesel M., et al. Identification of novel protein-protein interactions using a versatile mammalian tandem affinity purification expression system. Mol. Cell. Proteomics. 2:2003;1225-1233
54. Bockaert J., et al. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett. 546:2003;65-72
55. Becamel C., et al. A proteomic approach based on peptide affinity chromatography, 2-dimensional electrophoresis and mass spectrometry to identify multiprotein complexes interacting with membrane-bound receptors. Biol. Proced. Online. 4:2002;94-104
56. Devi L.A., Brady L.S. Dimerization of G-protein coupled receptors. Neuropsychopharmacology. 23:2000;S3-S4
57. Henningsen R., et al. Application of zwitterionic detergents to the solubilization of integral membrane proteins for two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2:2002;1479-1488
58. Zhang W., et al. Affinity enrichment of plasma membrane for proteomics analysis. Electrophoresis. 24:2003;2855-2863
59. Zhao Y., et al. Capillary high-performance liquid chromatography/mass spectrometric analysis of proteins from affinity-purified plasma membrane. Anal. Chem. 75:2003;3751-3757
60. Terrillon S., Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5:2004;30-34
61. Phizicky E., et al. Protein analysis on a proteomic scale. Nature. 422:2003;208-215
62. Stagljar I., Fields S. Analysis of membrane protein interactions using yeast-based technologies. Trends Biochem. Sci. 27:2002;559-563
63. Gavin A.C., et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature. 415:2002;141-147
64. Ho Y., et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature. 415:2002;180-183
65. Bécamel, C. et al. The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins. J. Biol. Chem. Feb 2004, published online ahead of print; doi: 10.1074/jbc.M312106200
66. Tsunoda S., et al. A multivalent PDZ-domain protein assembles signaling complexes in a G- protein-coupled cascade. Nature. 388:1997;243-249
67. Montell C. New light on TRP and TRPL. Mol. Pharmacol. 52:1997;755-763
68. Husi H., et al. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 3:2000;661-669
69. Husi H., Grant S.G. Proteomics of the nervous system. Trends Neurosci. 24:2001;259-266
70. Grant S.G., Husi H. Proteomics of multiprotein complexes: answering fundamental questions in neuroscience. Trends Biotechnol. 19:2001;S49-S54
71. Bell A.W., et al. Proteomics characterization of abundant Golgi membrane proteins. J. Biol. Chem. 276:2001;5152-5165
72. Schirmer E.C., Gerace L. Organellar proteomics: the prizes and pitfalls of opening the nuclear envelope. Genome Biol. 3:2002;1008
73. Bonhaus D.W., et al. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 287:1998;884-888
74. Berg K.A., et al. Novel actions of inverse agonists on 5-HT2C receptor systems. Mol. Pharmacol. 55:1999;863-872
75. Kenakin T. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 1:2002;103-110
76. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 42:2002;349-379
77. Chidiac P., et al. Inverse agonist activity of beta-adrenergic antagonists. Mol. Pharmacol. 45:1994;490-499
78. Chidiac P., et al. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Mol. Pharmacol. 50:1996;662-669
79. Azzi M., et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 100:2003;11406-11411
80. Archakov A.I., et al. Protein-protein interactions as a target for drugs in proteomics. Proteomics. 3:2003;380-391
81. Fernandez-Recio J., et al. Identification of protein-protein interaction sites from docking energy landscapes. J. Mol. Biol. 335:2004;843-865
82. Jones P.G., et al. Non-binding site modulation of G protein-coupled receptor signaling. Expert Opin. Ther. Pat. 9:1999;1641-1654
83. Gilchrist A., et al. Design and use of C-terminal minigene vectors for studying role of heterotrimeric G proteins. Methods Enzymol. 344:2002;58-69
84. Hébert T.E., et al. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271:1996;16384-16392
85. Goubaeva F., et al. Stimulation of cellular signaling and G protein subunit dissociation by G protein betagamma subunit-binding peptides. J. Biol. Chem. 278:2003;19634-19641
86. Schechtman D., Mochly-Rosen D. Isozyme-specific inhibitors and activators of protein kinase C. Methods Enzymol. 345:2002;470-489
87. Ashraf S.S., et al. Identification and characterization of peptide probes directed against PKCalpha conformations. J. Pept. Res. 61:2003;263-273
88. Songyang Z., et al. SH2 domains recognize specific phosphopeptide sequences. Cell. 72:1993;767-778
89. Davidson J.P., et al. Calorimetric and structural studies of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide inhibitors of Src SH2 domain binding. J. Am. Chem. Soc. 124:2002;205-215
90. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:2004;844-848
91. Morris M.C., et al. A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. J. Biol. Chem. 274:1999;24941-24946
92. Wurtele M., et al. Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO J. 22:2003;987-994
93. Rebois R.V., Hébert T.E. Protein complexes involved in heptahelical receptor-mediated signal transduction. Receptors Channels. 9:2003;169-194